First-in-human Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine fH1/DSP-0546LP

Influenza Clinical Trial

Official title:

A Single Center, Randomized, Double-blind, Placebo-controlled, First-in-human Phase 1 Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine "fH1/DSP-0546LP" After Intramuscular (IM) Administrations in Healthy Adults

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06460064
• Other study ID #: R2411201
• Secondary ID: JP19pc0101043202
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: June 26, 2024
• Est. completion date: March 27, 2026

Study information

• Verified date: May 2024
• Source: Sumitomo Pharma Co., Ltd.
• Contact: Sumitomo Pharma Co., Ltd.
• Phone: E-mail only
• Email: cc[@]sumitomo-pharma.co.jp
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a single center, randomized, double-blind, placebo-controlled, dose-finding, FIH, Phase 1 study to assess the safety, tolerability, and immunogenicity of the adjuvanted Universal Influenza Vaccine (fH1/DSP-0546LP) after IM administrations in healthy adults.

Description:

This will be a single center, randomized, placebo-controlled, double-blind study. In this study, safety, tolerability, and immunogenicity of fH1 formulated with DSP-0546LP will be assessed after IM administration in healthy adults aged 18 to 40 years.

This study includes 6 cohorts, with a combination of 2 dose levels of fH1 (2 and 8 μg), 3 dose levels of DSP-0546LP (2.5, 5, and 10 μg), and placebo. Each dose level of fH1 will be combined with the low, medium, and high dose level of DSP-0546LP. Subjects will receive 2 administrations at 3-week intervals.

Randomized subjects will undergo 11 visits including screening, 2 administration visits (Day 1 and Day 22 [± 2]), and follow-up visits on Day 4 (+1) (telephone contact), Day 8 (± 1), Day 25 (+1) (telephone contact), Day 29 (± 1), Day 36 (± 2), Day 50 (± 4), Day 204 (± 7), and Day 386 (± 10).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 144
• Est. completion date: March 27, 2026
• Est. primary completion date: March 27, 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

1. Healthy adult male or female subject between 18 and 40 years of age at the time of informed consent.

2. Subject who is fully informed of and understands the objectives, procedures, anticipated side effects of the vaccine and risks of the study and who voluntarily provides written consent to participate in the study.

3. Subject's body weight is equal to or more than 50 kg, and body mass index is at least 18 kg/m2 but no more than 30 kg/m2 at screening.

4. Subject willing and able to comply with the study requirements, including laboratory tests and reporting symptoms.

5. A male subject with a female partner of childbearing potential must agree to use adequate and reliable contraception (e.g., using condom or have had vasectomy with proven sterility for male and using contraceptive agents, diaphragm, intrauterine devices (IUDs), or bilateral tubal ligation for female partner) from informed consent until at least 30 days after last administration of the study vaccine.

6. A female subject is eligible for this study if she is neither pregnant nor breastfeeding and 1 of the following:

1. Of non childbearing potential (i.e., women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses in greater than or equal to 1 year).

2. Of childbearing potential but has been and agrees to continue practicing highly effective contraception from informed consent until at least 30 days after the last administration. Highly effective methods of contraception include 1 or more of the following:

• a female subject who is abstinent or have a sexual relationship with sole female partner;

• male partner who is sterile (vasectomized) prior to the female subject's entry into the study and is the sole sexual partner for the female subject;

• hormonal (oral, intravaginal, transdermal, implantable or injectable), which is associated with inhibition of ovulation;

• an intrauterine hormone-releasing system;

• an intrauterine device with a documented failure rate of < 1%;

• bilateral tubal occlusion.

7. A female subject who is premenopausal and of childbearing potential must have a negative urine pregnancy-test result at screening, on Days 1 and 22.

8. Subject must agree not to donate sperm or eggs from informed consent until at least 30 days after last administration of the study vaccine.

Exclusion Criteria:

1. Subject with a history of clinically significant cardiovascular, hepatic, renal, endocrine, gastrointestinal, hematological, respiratory, psychiatric or neurologic disease, and who is considered ineligible for the study by the Principal Investigator (PI) or sub Investigator.

2. Subject with other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior that may increase the risk of study participation or, in the Investigator's judgement, make the subject inappropriate for the study.

3. Subject immunocompromised with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.

4. Subject with a history or evidence of autoimmune disease or known immunodeficiency of any cause or severe allergy.

5. Subject who receives chronic treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, e.g., for cancer or an autoimmune disease, within 60 days before the Screening Visit or planned receipt throughout the study. If systemic corticosteroids have been administered short term (< 14 days) for treatment of an acute illness, subjects should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before first administration. Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.

6. Subject with a history of severe adverse reaction associated with a vaccine and/or a known or suspected allergic reaction (e.g., anaphylaxis) or hypersensitivity to any component of the investigational product including egg protein.

7. Subject with a history of substance abuse or drug abuse. If there is any doubt about the correctness of the information provided by the subject (history) or observation of a behavior that raises concerns about drug use, drug screening will be conducted at the Screening Visit or prior to first administration.

8. Subject with a positive serology (hepatitis B surface antigen, hepatitis C antibody, human immunodeficiency virus antigen/antibody) at screening.

9. Subject with any clinically significant abnormal clinical laboratory value (hematology, serum chemistry, urinalysis, coagulation) determined by the PI or sub-Investigator at screening.

10. Subject with a history of excessive alcohol consumption (defined as drinking at least 21 units of alcohol beverage per week for a man and 14 units of alcohol beverage per week for a woman) within 6 months of the Screening Visit. Following common drinks contain 1 unit of alcohol: 300 ml beer [4% alcohol by volume (ABV)], 100 ml of wine (12% ABV), 30 ml of spirits (40% ABV).

11. Subject who drinks large quantities of caffeinated beverages (coffee, tea, green tea, cola, tonic drink, etc) (approximately 1.8 L daily or more).

12. Subject with a history of tobacco (including electronic cigarette) dependency or subject who smokes = 20 cigarettes daily (excluding subject who stopped smoking more than 2 years ago).

13. Subject who has received seasonal flu vaccine within a year prior to the Screening Visit.

14. Subject who has experienced significant blood loss or donated blood (= 400 mL) within 90 days prior to the first administration or donated 200 mL of blood or more within 30 days prior to the first administration; has donated blood components within 14 days prior to the first administration.

15. Subject who has received blood/plasma products or immunoglobulins within 6 months prior to the Screening Visit.

16. Subject who has received any investigational drug or who is currently participating or has participated in a clinical study within 90 days prior to the Screening Visit.

17. Subject who has participated in a clinical study of any influenza vaccine, or any investigational vaccine or experimental influenza viral challenge delivered directly to the respiratory tract within a year prior to the first administration.

18. Subject with a history of hospitalization (excluding hospitalization for medical checkup) for at least one night within 45 days prior to the Screening Visit.

19. Subject who has used prescription or over-the-counter medications except chronic medication and contraceptives for female subjects within 7 days or 5 half-lives prior to the first administration.

20. In the Investigator's judgement, the subject has current symptoms suggestive of an acute infection, or presence of long-term medical, neurologic, or psychiatric sequalae of prior COVID-19.

21. Subject who has received any other licensed vaccine within 28 days prior to screening or who is planning to receive any vaccine up to 28 days after the last vaccine administration.

22. Subject who is a staff member of the clinical site/Sponsor/Contract research organization (CRO) or the relative of a staff member.

23. Subject who is in the opinion of the PI or sub-Investigator, unsuitable in any other way to participate in this study.

24. Subject with bleeding disorder that would, in the opinion of the Investigator, contraindicate IM injection.

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• fH1 2 ug
2 administrations at 3-week intervals.
• fH1 8 ug
2 administrations at 3-week intervals.
• DSP-0546LP 2.5 ug
2 administrations at 3-week intervals.
• DSP-0546LP 5 ug
2 administrations at 3-week intervals.
• DSP-0546LP 10 ug
2 administrations at 3-week intervals.
• Placebo
2 administrations at 3-week intervals.

Locations

Country	Name	City	State
Belgium	Center for Vaccinology	Gent	Corneel Heymanslaan 10

Sponsors (1)

Lead Sponsor	Collaborator
Sumitomo Pharma Co., Ltd.

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of solicited local adverse events (AEs) during a 7-day follow-up period after each administration.	Solicited local AEs: pain, redness, swelling, induration, warmth, and pruritus at injection site	7 days after each administration
Primary	Incidence of solicited systemic AEs during a 7-day follow-up period after each administration.	Solicited systemic AEs: feverishness, chills, myalgia, fatigue, headache, nausea, arthralgia, malaise, and body temperature (measured axillary)	7 days after each administration
Primary	Incidence of unsolicited AEs from the first administration to 4 weeks after the second administration.	Clinical observations, clinical laboratory values and vital signs	From the first administration to 4 weeks after the second administration.
Primary	Incidence of serious adverse events (SAEs), AEs leading to study discontinuation, and adverse events of special interest throughout the study period.		From the first administration to 52-week follow-up after the second administration
Secondary	Percentage of subjects with increased immunoglobulin (Ig) G response to long alpha helix (LAH) after administration of fH1/DSP-0546LP.		From the day of the first administration to 52-week follow-up after the second administration
Secondary	Percentage of subjects with increased neuraminidase inhibition antibody titer after administration of fH1/DSP-0546LP.		From the day of the first administration to 1 week after the second administration.
Secondary	Seroconversion rate (SCR) of hemagglutination inhibition (HAI) antibody titers after administration of fH1/DSP-0546LP.	SCR is defined as the percentage of subjects with either a baseline (Day 1) HAI titer < 1:10 and post-administration titer = 1:40, or baseline titer = 1:10 and = 4-fold increase in post-administration titer.	From the day of the first administration to 1 week after the second administration.